Stability of ursodiol 25 mg/mL in an extemporaneously prepared oral liquid

被引:5
作者
Mallett, MS
Hagan, RL
Peters, DA
机构
[1] WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,MORRIS PLAINS,NJ 07950
[2] DAVID GRANT MED CTR,DEPT PHARM,PHARM SUPPORT SERV,CLIN INVEST FACIL,TRAVIS AFB,CA
关键词
capsules; cholelitholytic agents; compounding; formulations; glycerin; incompatibilities; orange syrup; stability; storage; suspending agents; suspensions; sweetening agents; temperature; ursodiol; vehicles;
D O I
10.1093/ajhp/54.12.1401
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The stability of ursodiol in an extemporaneously formulated oral liquid was studied. A suspension was prepared by combining the contents of commercially available 300-mg capsules of ursodiol with glycerin, Ora-Plus (Paddock Laboratories), and orange syrup. A second formulation was prepared by combining ursodiol capsules with sterile water for irrigation. The final concentration of ursodiol in each formulation was 25 mg/mL. Six samples of each preparation were stored in 4-oz amber plastic prescription bottles protected from light. Three were stored at 22-23 degrees C and three were refrigerated al 2-6 degrees C. Immediately after preparation and at 7, 15, 30, 45, and 60 days, samples were obtained and frozen until assay by high-performance liquid chromatography. On day 60 the mean percentage of the initial ursodiol concentration remaining was 108.4% for the suspension stored at room temperature and 103.3% for the refrigerated suspension. The ursodiol-in-water formulation was not analyzed because of rapid settling of ursodiol. Ursodiol 25 mg/mL in an oral liquid prepared extemporaneously from capsules and sweetened vehicle was stable for 60 days when stored in amber plastic bottles at 22-23 and 2-6 degrees C. Addition of ursodiol powder to water without a suspending agent resulted in a liquid formulation with a high variability in content uniformity.
引用
收藏
页码:1401 / 1404
页数:4
相关论文
共 6 条
[1]   EFFECTS OF URSODEOXYCHOLIC ACID ON LIVER-FUNCTION IN PATIENTS WITH CYSTIC-FIBROSIS AND CHRONIC CHOLESTASIS [J].
GALABERT, C ;
MONTET, JC ;
LENGRAND, D ;
LECUIRE, A ;
SOTTA, C ;
FIGARELLA, C ;
CHAZALETTE, JP .
JOURNAL OF PEDIATRICS, 1992, 121 (01) :138-141
[2]  
HANNON JF, 1984, HDB PACKAGE ENG
[3]  
JOHNSON CE, 1995, AM J HEALTH-SYST PH, V52, P1798
[4]   URSODEOXYCHOLIC ACID THERAPY IN THE TREATMENT OF BILIARY ATRESIA [J].
NITTONO, H ;
TOKITA, A ;
HAYASHI, M ;
WATANABE, T ;
OBINATA, K ;
NAKATSU, N ;
MIYANO, T .
BIOMEDICINE & PHARMACOTHERAPY, 1989, 43 (01) :37-41
[5]  
Poupon R E, 1992, Prog Liver Dis, V10, P219
[6]   EFFECTS OF URSODEOXYCHOLIC ACID TREATMENT ON ESSENTIAL FATTY-ACID DEFICIENCY IN PATIENTS WITH BILIARY ATRESIA [J].
YAMASHIRO, Y ;
OHTSUKA, Y ;
SHIMIZU, T ;
NITTONO, H ;
URAO, M ;
MIYANO, T ;
KAWAKAMI, S ;
HAYASAWA, H .
JOURNAL OF PEDIATRIC SURGERY, 1994, 29 (03) :425-428